Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Interest Expenses (2022 - 2025)

Taysha Gene Therapies' Interest Expenses history spans 4 years, with the latest figure at $15000.0 for Q3 2025.

  • For Q3 2025, Interest Expenses fell 37.5% year-over-year to $15000.0; the TTM value through Sep 2025 reached $73000.0, down 90.79%, while the annual FY2024 figure was $102000.0, 97.96% down from the prior year.
  • Interest Expenses for Q3 2025 was $15000.0 at Taysha Gene Therapies, down from $17000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.5 million in Q3 2022 and bottomed at $15000.0 in Q3 2025.
  • The 4-year median for Interest Expenses is $672000.0 (2022), against an average of $690200.0.
  • The largest annual shift saw Interest Expenses surged 104.46% in 2023 before it tumbled 98.37% in 2024.
  • A 4-year view of Interest Expenses shows it stood at $1.3 million in 2022, then tumbled by 45.36% to $713000.0 in 2023, then crashed by 96.91% to $22000.0 in 2024, then plummeted by 31.82% to $15000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Interest Expenses are $15000.0 (Q3 2025), $17000.0 (Q2 2025), and $19000.0 (Q1 2025).